INmune Bio is a biotechnology business based in the US. INmune Bio shares (INMB) are listed on the NASDAQ and all prices are listed in US Dollars. INmune Bio employs 10 staff and has a trailing 12-month revenue of around $279,000.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $7.10 |
|---|---|
| 52-week range | $5.75 - $11.26 |
| 50-day moving average | $8.63 |
| 200-day moving average | $8.02 |
| Wall St. target price | $17.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.50 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.1 from 2023-09-21
| 1 week (2023-09-15) | -10.58% |
|---|---|
| 1 month (2023-08-23) | -13.41% |
| 3 months (2023-06-23) | -22.06% |
| 6 months (2023-03-23) | 7.66% |
| 1 year (2022-09-23) | 2.75% |
|---|---|
| 2 years (2021-09-23) | -63.31% |
| 3 years (2020-09-23) | 10.31 |
| 5 years (2018-09-19) | N/A |
| Revenue TTM | $279,000 |
|---|---|
| Gross profit TTM | $374,000 |
| Return on assets TTM | -20.5% |
| Return on equity TTM | -44.11% |
| Profit margin | 0% |
| Book value | $2.82 |
| Market Capitalization | $150.6 million |
TTM: trailing 12 months
We're not expecting INmune Bio to pay a dividend over the next 12 months.
Over the last 12 months, INmune Bio's shares have ranged in value from as little as $5.7501 up to $11.258. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while INmune Bio's is 1.9442. This would suggest that INmune Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
INmune Bio, Inc. , a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc. ; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.